M&T Bank Corp Has $25.90 Million Stock Holdings in Zoetis Inc. $ZTS

M&T Bank Corp reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 205,815 shares of the company’s stock after selling 10,722 shares during the quarter. M&T Bank Corp’s holdings in Zoetis were worth $25,896,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZTS. Global Wealth Strategies & Associates bought a new position in shares of Zoetis in the 4th quarter worth $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter worth about $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZTS shares. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Thursday, February 26th. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday. Finally, UBS Group dropped their target price on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $151.75.

Zoetis Trading Down 1.2%

Shares of Zoetis stock opened at $112.81 on Tuesday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a fifty day simple moving average of $119.93 and a two-hundred day simple moving average of $124.53. Zoetis Inc. has a 1 year low of $112.10 and a 1 year high of $172.23. The company has a market capitalization of $47.45 billion, a price-to-earnings ratio of 18.74, a P/E/G ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts forecast that Zoetis Inc. will post 7.01 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. Zoetis’s payout ratio is currently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.